公开(公告)号：TWI437003B

公开(公告)日：2014-05-11

申请号：TW097148899

申请日：2008-12-16

Applicant: 萊根製藥公司 ,  LIGAND PHARMACEUTICALS INCORPORATED

Inventor： 志林 ,  ZHI, LIN

IPC: C07D498/04 ,  C07D207/08 ,  A61K31/402 ,  A61K31/538 ,  A61P5/26

CPC classification number: C07D207/09 ,  A61K31/401 ,  A61K31/402 ,  A61K31/5383 ,  A61K45/06 ,  C07D207/08 ,  C07D207/16 ,  C07D498/04 ,  Y02A50/401

公开(公告)号：TW202003453A

公开(公告)日：2020-01-16

申请号：TW108104800

申请日：2019-02-13

Applicant: 美商利根德製藥公司 ,  LIGAND PHARMACEUTICALS INCORPORATED ,  瑞士商美塔凡科學公司 ,  METAVANT SCIENCES GMBH

Inventor： 智 林 ,  ZHI, LIN ,  韓德森 伊恩 ,  HENDERSON, IAN ,  卡洛科 約瑟夫 ,  KALOKO, JOSEPH ,  奧斯特豪 馬丁 ,  OSTERHOUT, MARTIN

IPC: C07C309/15 ,  C07C303/32 ,  C07C303/44 ,  C07C309/24 ,  A61P3/10

Abstract: 本發明提供具有升糖素受體拮抗劑或反促效劑(inverse agonist)活性之固態形式的化合物，包括其鏡像異構純的形式以及其藥學上可接受的鹽類或共晶體及前藥。此外，本發明提供藥學組成物及方法，其係供治療、預防、改善一或多種升糖素受體拮抗劑所適應的至少一種病況、疾病、或障礙(包括第一型及第二型糖尿病、胰島素抗性、高血糖症、酮酸症、或酮病)或延緩其發病的時間或降低其發展或進展的風險。

Abstract in simplified Chinese: 本发明提供具有升糖素受体拮抗剂或反促效剂(inverse agonist)活性之固态形式的化合物，包括其镜像异构纯的形式以及其药学上可接受的盐类或共晶体及前药。此外，本发明提供药学组成物及方法，其系供治疗、预防、改善一或多种升糖素受体拮抗剂所适应的至少一种病况、疾病、或障碍(包括第一型及第二型糖尿病、胰岛素抗性、高血糖症、酮酸症、或酮病)或延缓其发病的时间或降低其发展或进展的风险。

公开(公告)号：US11358931B2

公开(公告)日：2022-06-14

申请号：US16983617

申请日：2020-08-03

Applicant: Ligand Pharmaceuticals Incorporated

Inventor： Lin Zhi

IPC: C07D207/09 ,  C07D207/08 ,  A61P5/28 ,  C07D498/04 ,  A61K31/402 ,  A61K31/5383 ,  A61K45/06 ,  C07D207/16 ,  A61K31/401

Abstract: Provided herein are compounds, such as compounds of Formula I, that bind to androgen receptors and/or modulate activity of androgen receptors. Also provided are methods for making and using such compounds. Also provided are compositions including such compounds and methods for making and using such compositions.

公开(公告)号：US11278559B2

公开(公告)日：2022-03-22

申请号：US16557768

申请日：2019-08-30

Applicant: LIGAND PHARMACEUTICALS INCORPORATED

Inventor： Lin Zhi

IPC: A01N43/04 ,  A61K31/70 ,  A61K31/7072 ,  C07F9/6574 ,  C07F9/6584 ,  C07F9/655 ,  C07F9/09 ,  C07F9/6571 ,  A61K9/00 ,  A61K31/661 ,  A61K31/6615 ,  A61K31/663 ,  A61K31/675

Abstract: Provided herein are prodrug compounds, their preparation and their uses, such as treating liver diseases or nonliver diseases via intervening in molecular pathways in the liver.

公开(公告)号：US10730831B2

公开(公告)日：2020-08-04

申请号：US16148798

申请日：2018-10-01

Applicant: Ligand Pharmaceuticals Incorporated

Inventor： Lin Zhi

IPC: C07D207/08 ,  C07D207/09 ,  C07D498/04 ,  A61K31/402 ,  A61K31/5383 ,  A61K45/06 ,  C07D207/16 ,  A61K31/401

Abstract: Provided herein are compounds, such as compounds of Formula I, that bind to androgen receptors and/or modulate activity of androgen receptors. Also provided are methods for making and using such compounds. Also provided are compositions including such compounds and methods for making and using such compositions.

公开(公告)号：US10106500B2

公开(公告)日：2018-10-23

申请号：US15590884

申请日：2017-05-09

Applicant: Ligand Pharmaceuticals Incorporated

Inventor： Lin Zhi

IPC: C07D207/08 ,  C07D207/09 ,  A61K31/402 ,  C07D498/04 ,  A61K31/5383 ,  A61K45/06

Abstract: Provided herein are compounds, such as compounds of Formula I, that bind to androgen receptors and/or modulate activity of androgen receptors. Also provided are methods for making and using such compounds. Also provided are compositions including such compounds and methods for making and using such compositions.

公开(公告)号：US09675583B2

公开(公告)日：2017-06-13

申请号：US14827228

申请日：2015-08-14

Applicant: Ligand Pharmaceuticals Incorporated

Inventor： Lin Zhi

IPC: C07D207/08 ,  A61K31/401 ,  C07D498/04 ,  A61K31/402 ,  A61K31/5383 ,  A61K45/06 ,  C07D207/09 ,  C07D207/16

CPC classification number: C07D207/09 ,  A61K31/401 ,  A61K31/402 ,  A61K31/5383 ,  A61K45/06 ,  C07D207/08 ,  C07D207/16 ,  C07D498/04 ,  Y02A50/401

Abstract: Provided herein are compounds, such as compounds, of Formula I, that bind to androgen receptors and/or modulate activity of androgen receptors. Also provided are methods for making and using such compounds. Also provided are compositions including such compounds and methods for making and using such compositions.

公开(公告)号：US20160347783A1

公开(公告)日：2016-12-01

申请号：US15034757

申请日：2014-11-19

Applicant: LIGAND PHARMACEUTICALS INCORPORATED

Inventor： Lin Zhi

IPC: C07H19/10

CPC classification number: C07H19/10 ,  C07H19/11

Abstract: Some embodiments of the present invention include nucleoside 5′-monophosphate derivative compounds, their preparation and their uses. In some embodiments, such compounds are useful to treat hepatitis C viral infections.

Abstract translation: 本发明的一些实施方案包括核苷5'-单磷酸衍生物化合物，其制备及其用途。 在一些实施方案中，这些化合物可用于治疗丙型肝炎病毒感染。

公开(公告)号：US20160311888A1

公开(公告)日：2016-10-27

申请号：US15206063

申请日：2016-07-08

Applicant: LIGAND PHARMACEUTICALS INCORPORATED

Inventor： Roland Buelow

IPC: C07K16/00 ,  A01K67/027 ,  C12N15/85 ,  C12N5/075

CPC classification number: C07K16/00 ,  A01K67/0276 ,  A01K67/0278 ,  A01K2207/15 ,  A01K2217/072 ,  A01K2217/075 ,  A01K2267/01 ,  C07K2317/14 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/51 ,  C07K2317/76 ,  C12N5/0609 ,  C12N9/22 ,  C12N15/8509 ,  C12N2015/8518 ,  C12N2510/00

Abstract: The invention relates to transgenic animals lacking endogenous Ig and capable of producing transgenic antibodies, as well as methods of making the same. The invention further relates to methods for producing transgenic antibodies in such animals, and transgenic antibodies so produced.

公开(公告)号：US09359285B2

公开(公告)日：2016-06-07

申请号：US14519053

申请日：2014-10-20

Applicant: Ligand Pharmaceuticals Incorporated

Inventor： Lin Zhi ,  Robert I. Higuchi ,  Cornelis Arjan Van Oeveren ,  Thomas Lot Stevens Lau

IPC: C07D277/46 ,  A01N43/42 ,  C07C211/52 ,  C07C255/58 ,  C07F7/18 ,  C07D207/27 ,  C07D207/08 ,  C07D209/12 ,  C07D211/60 ,  C07D211/22 ,  C07C205/55

CPC classification number: C07C211/52 ,  C07C205/55 ,  C07C255/58 ,  C07C2601/08 ,  C07D207/08 ,  C07D207/09 ,  C07D207/12 ,  C07D207/16 ,  C07D207/26 ,  C07D207/27 ,  C07D207/46 ,  C07D209/04 ,  C07D209/08 ,  C07D209/12 ,  C07D211/22 ,  C07D211/56 ,  C07D211/60 ,  C07D215/04 ,  C07D215/18 ,  C07D265/36 ,  C07D295/073 ,  C07F7/1804 ,  G01N2333/723

Abstract: Provided herein are compounds having a structure selected from among Formula (I), Formula (II), Formula (III), Formula (IV), Formula (V) and Formula (VI) that are androgen receptor modulators and/or androgen receptor binding agents. Also disclosed are methods of making and using such compounds, including, but not limited to, using such compounds for treating various conditions.